Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 13/20 | 0.62 |
| ▸ | F13A1 | P00488 | 10/20 | 0.62 |
| ▸ | TGM1 | P22735 | 7/20 | 0.62 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30307817 | 1.00 | TGM2 (0.62) | TGM2F13A1TGM1TGM3ALDH1A1 | |
| SCHEMBL27200534 | 0.84 | TGM2 (0.64) | TGM2F13A1TGM1PKMGPR119 | |
| SCHEMBL5442111 | 0.84 | TGM2 (0.64) | TGM2F13A1TGM1TGM3ALDH1A1 | |
| SCHEMBL20502523 | 0.83 | ALDH1A1 (0.53) | TGM2F13A1TGM1ALDH1A1PKM | |
| SCHEMBL2378926 | 0.83 | TGM2 (0.56) | TGM2F13A1TGM1PKMGPR119 | |
| SCHEMBL23620982 | 0.83 | GPR119 (0.52) | TGM2F13A1GPR119CA2 | |
| SCHEMBL31165481 | 0.83 | TGM2 (0.56) | TGM2F13A1TGM1PKMGPR119 | |
| SCHEMBL23620938 | 0.82 | GPR119 (0.52) | GPR119CA2 | |
| SCHEMBL30307819 | 0.82 | GPR119 (0.52) | GPR119CA2 | |
| SCHEMBL23620954 | 0.82 | GPR119 (0.55) | GPR119CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3596059-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS DUAL ATX/CA INHIBITORS | HOFFMANN LA ROCHE (CH) | 2024-04-24 | — | — | EP | disclosed |
| US-11059794-B2 | Heterocyclic compounds useful as dual ATX/CA inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2021-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11059794-B2 | Heterocyclic compounds useful as dual ATX/CA inhibitors | ATXN2, ATXN2L, ATXN10 | TGM2 2068/4885F13A1 947/4885TGM1 1830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.